一份多国报告，旨在描述囊性纤维化患者中 SARS-CoV-2 感染的特征。
A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis.
机构信息
Cystic Fibrosis Trust, London, UK.
Monash University, Melbourne, Australia.
出版信息
J Cyst Fibros. 2020 May;19(3):355-358. doi: 10.1016/j.jcf.2020.04.012. Epub 2020 Apr 25.
Abstract
UNLABELLED
Information is lacking on the clinical impact of the novel coronavirus, SARS-CoV-2, on people with cystic fibrosis (CF). Our aim was to characterise SARS-CoV-2 infection in people with cystic fibrosis.
METHODS
Anonymised data submitted by each participating country to their National CF Registry was reported using a standardised template, then collated and summarised.
RESULTS
40 cases have been reported across 8 countries. Of the 40 cases, 31 (78%) were symptomatic for SARS-CoV-2 at presentation, with 24 (60%) having a fever. 70% have recovered, 30% remain unresolved at time of reporting, and no deaths have been submitted.
CONCLUSIONS
This early report shows good recovery from SARS-CoV-2 in this heterogeneous CF cohort. The disease course does not seem to differ from the general population, but the current numbers are too small to draw firm conclusions and people with CF should continue to strictly follow public health advice to protect themselves from infection.
摘要
未加标签
关于新型冠状病毒（SARS-CoV-2）对囊性纤维化（CF）患者的临床影响，信息有限。我们的目的是描述囊性纤维化患者的 SARS-CoV-2 感染情况。
方法
通过标准化模板报告了每个参与国家向其国家 CF 登记处提交的匿名数据，然后对数据进行了整理和总结。
结果
8 个国家报告了 40 例病例。在这 40 例病例中，31 例（78%）在出现时出现 SARS-CoV-2 症状，24 例（60%）有发热。70%的患者已康复，30%的患者在报告时仍未解决，目前没有死亡病例报告。
结论
本早期报告显示，在这一异质性 CF 队列中，SARS-CoV-2 的恢复情况良好。疾病过程似乎与普通人群没有区别，但目前的数字太小，无法得出明确的结论，CF 患者仍应继续严格遵循公共卫生建议，以保护自己免受感染。
相似文献
1
A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis.
J Cyst Fibros. 2020 May;19(3):355-358. doi: 10.1016/j.jcf.2020.04.012. Epub 2020 Apr 25.
2
COVID-19 in lung-transplanted and cystic fibrosis patients: Be careful.
J Cyst Fibros. 2020 May;19(3):e16-e17. doi: 10.1016/j.jcf.2020.03.021. Epub 2020 May 10.
3
Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey.
Respir Med. 2020 Aug-Sep;170:106062. doi: 10.1016/j.rmed.2020.106062. Epub 2020 Jun 8.
4
Symptom Profiles and Risk Factors for Hospitalization in Patients With SARS-CoV-2 and COVID-19: A Large Cohort From South America.
Gastroenterology. 2020 Sep;159(3):1148-1150. doi: 10.1053/j.gastro.2020.05.014. Epub 2020 May 8.
5
COVID-19 Infection versus Influenza (Flu) and Other Respiratory Illnesses.
Am J Respir Crit Care Med. 2020 Nov 15;202(10):P27-P28. doi: 10.1164/rccm.2020C16.
6
Pediatric Characteristics of 2019 Novel Coronavirus: Review of Available Published Literature.
Clin Pediatr (Phila). 2020 Sep;59(9-10):849-852. doi: 10.1177/0009922820920017. Epub 2020 Apr 15.
7
COVID-19 in a complex obstetric patient with cystic fibrosis.
Infect Dis Health. 2020 Nov;25(4):239-241. doi: 10.1016/j.idh.2020.07.002. Epub 2020 Jul 23.
8
SARS-Coronavirus-2 and acute urticaria.
Int J Dermatol. 2020 Jul;59(7):867-868. doi: 10.1111/ijd.14950. Epub 2020 May 22.
9
A call from the European Academy of Neurology on COVID-19.
Lancet Neurol. 2020 Jun;19(6):482. doi: 10.1016/S1474-4422(20)30151-4. Epub 2020 May 26.
10
Urticarial eruption in coronavirus disease 2019 infection: a case report in Tangerang, Indonesia.
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e372-e373. doi: 10.1111/jdv.16622. Epub 2020 Jun 4.
引用本文的文献
1
Managing an ageing cystic fibrosis population: challenges and priorities.
Eur Respir Rev. 2025 May 14;34(176). doi: 10.1183/16000617.0261-2024. Print 2025 Apr.
2
Uncomplicated SARS-CoV-2 Infections with Preserved Lung Function in Pediatric Patients with Cystic Fibrosis: A Three-Year Single-Centre Experience.
J Clin Med. 2025 Apr 25;14(9):2979. doi: 10.3390/jcm14092979.
3
Living with cystic fibrosis during the COVID-19 pandemic: An interpretive description of healthcare access from patients with cystic fibrosis and their providers in Alberta, Canada.
PLoS One. 2025 May 2;20(5):e0322911. doi: 10.1371/journal.pone.0322911. eCollection 2025.
4
The efficacy of COVID-19 vaccination in cystic fibrosis patients: a systematic review.
BMC Infect Dis. 2025 Mar 13;25(1):358. doi: 10.1186/s12879-025-10736-6.
5
A Repurposed Drug Interferes with Nucleic Acid to Inhibit the Dual Activities of Coronavirus Nsp13.
ACS Chem Biol. 2024 Jul 19;19(7):1593-1603. doi: 10.1021/acschembio.4c00244. Epub 2024 Jul 9.
6
Occurrence of COVID-19 in cystic fibrosis patients: a review.
Front Microbiol. 2024 Apr 17;15:1356926. doi: 10.3389/fmicb.2024.1356926. eCollection 2024.
7
Beyond Borders of the Cell: How Extracellular Vesicles Shape COVID-19 for People with Cystic Fibrosis.
Int J Mol Sci. 2024 Mar 27;25(7):3713. doi: 10.3390/ijms25073713.
8
Adapting, restarting, and terminating a randomised control trial for people with cystic fibrosis: Reflections on the impact of the COVID-19 pandemic upon research in a clinical population.
Contemp Clin Trials Commun. 2024 Mar 27;39:101294. doi: 10.1016/j.conctc.2024.101294. eCollection 2024 Jun.
9
SARS-CoV-2 envelope protein impairs airway epithelial barrier function and exacerbates airway inflammation via increased intracellular Cl concentration.
Signal Transduct Target Ther. 2024 Mar 25;9(1):74. doi: 10.1038/s41392-024-01753-z.
10
The clinical features and impact of SARS-CoV-2/COVID-19 infection in children with Cystic Fibrosis (CF): A Qatari experience.
Qatar Med J. 2023 Dec 12;2023(3):19. doi: 10.5339/qmj.2023.19. eCollection 2023.
本文引用的文献
1
Impact of COVID-19 on people with cystic fibrosis.
Lancet Respir Med. 2020 May;8(5):e35-e36. doi: 10.1016/S2213-2600(20)30177-6. Epub 2020 Apr 15.
2
Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?
Lancet Respir Med. 2020 May;8(5):436-438. doi: 10.1016/S2213-2600(20)30167-3. Epub 2020 Apr 3.
3
Estimates of the severity of coronavirus disease 2019: a model-based analysis.
Lancet Infect Dis. 2020 Jun;20(6):669-677. doi: 10.1016/S1473-3099(20)30243-7. Epub 2020 Mar 30.
4
False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases.
Korean J Radiol. 2020 Apr;21(4):505-508. doi: 10.3348/kjr.2020.0146. Epub 2020 Mar 5.
5
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
6
Clinical Characteristics of Coronavirus Disease 2019 in China.
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
7
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
8
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
9
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
10
Impact of the A (H1N1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis.
J Cyst Fibros. 2011 Sep;10(5):370-6. doi: 10.1016/j.jcf.2011.06.004. Epub 2011 Jul 12.
Zotero 插件